Saillard C, Mokart D, Lemiale V, Azoulay E
Hematology Department, Institut Paoli Calmettes, Marseille, France -
Minerva Anestesiol. 2014 Jun;80(6):712-25. Epub 2013 Nov 26.
Acute respiratory failure (ARF) in cancer patients remains a frequent and severe complication, despite the general improved outcome over the last decade. The survival of cancer patients requiring ventilatory support in Intensive Care Unit (ICU) has dramatically improved over the last years. The diagnostic approach, including an invasive strategy using fiber optic bronchoscopy or a non-invasive strategy, must be effective to identify a diagnostic, as it is a crucial prognostic factor. The use of non-invasive ventilation (NIV) instead of invasive mechanical ventilation (IMV), has contributed to decrease mortality, but NIV has to be used in appropriate situations. Indeed, NIV failure (i.e., need for IMV) is deleterious. Classical prognostic factors are not relevant anymore. The number of organ failure at admission and over the first 7 ICU days governs outcomes. Ventilatory support can thus be included in different management contexts: full code management with unlimited use of life sustaining therapies, full code management for a limited period, no-intubation decision, or the use of palliative NIV. The objectives of this review article are to summarize the modified ARF diagnostic and therapeutic management, induced by improvements in both intensive care and onco-hematologic management and recent literature data.
尽管在过去十年中总体预后有所改善,但癌症患者的急性呼吸衰竭(ARF)仍然是一种常见且严重的并发症。在过去几年中,需要在重症监护病房(ICU)接受通气支持的癌症患者的生存率有了显著提高。诊断方法,包括使用纤维支气管镜的侵入性策略或非侵入性策略,必须有效地做出诊断,因为这是一个关键的预后因素。使用无创通气(NIV)而非有创机械通气(IMV)有助于降低死亡率,但NIV必须在适当的情况下使用。事实上,NIV失败(即需要IMV)是有害的。传统的预后因素已不再相关。入院时和最初7个ICU日的器官衰竭数量决定了预后。因此,通气支持可纳入不同的管理背景:无限制使用生命维持疗法的全代码管理、有限期的全代码管理、不插管决策或使用姑息性NIV。这篇综述文章的目的是总结由重症监护和肿瘤血液学管理的改进以及近期文献数据所引发的ARF诊断和治疗管理的变化。